Replies to post #6202 on Entremed (ENMD)

[rubberchicken]

Thank you, that's very helpful.

[docaaron1]

Interesting to note that Enmd has turned MKC-1 from a toxic drug into a "well-tolerated without evidence of cumulative toxicity" drug. They did it by their keen observation and anti-angiogenesis knowledge and applied it to MKC-1 to get some modest results. I hope the people at Roche are pleasantly surprised.

"We plan to evaluate our options for either randomized single- agent or combination studies in breast cancer once this study is complete." Does this mean a phase IIb study is next or possibly a phase III study? I really don't know.

Aaron
(Also posted on Yahoo board)